© 2002 by the American Diabetes Association, Inc.
Effects of Fasting on Physiologically Pulsatile Insulin Release in Healthy Humans
1 Department of Endocrinology and Metabolism M, Aarhus University Hospital, Aarhus, Denmark
Insulin is released as secretory bursts superimposed on basal release. The overall contribution of secretory bursts was recently quantified as at least 75%, and the main regulation of insulin secretion is through perturbation of the amount of insulin released and the frequency of these secretory bursts. The mode of delivery of insulin into the circulation seems important for insulin action, and therefore physiological conditions that alter the pattern of insulin release may affect insulin action through this mechanism. To assess the mechanisms by which fasting changes the amount of insulin released and the frequency, amplitude, and overall contribution of pulsatile insulin secretion, we used a validated deconvolution model to examine pulsatile insulin secretion during 10 and 58 h of fasting in seven healthy subjects. The subjects were studied for 75 min before (075 min) and 75 min during (115190 min) a glucose infusion (2.5 mg · kg-1 · min-1). We found that the pulsatile insulin release pattern was preserved and that, at fasting, overall insulin release is adjusted to needs by a reduced amount of insulin released (10.1 ± 1.7 vs. 16.0 ± 3.2 pmol/l/pulse, P < 0.05) but similar frequency (6.3 ± 0.4 vs. 6.1 ± 0.4 min/pulse) of the insulin secretory bursts. In both states, glucose infusion caused an increase (P < 0.05) in amount (100200%) and frequency ( 20%). The impact of increased glucose concentration on pulse frequency seems distinct for in vivo versus in vitro pulsatile insulin secretion and may indicate the presence of a glucose-sensitive pacemaker, which initiates the coordinated secretory bursts. Increased insulin/C-peptide ratio at long-term fasting (6.0 vs. 9.1%, P < 0.01) indicates that the changes in insulin release patterns may be accompanied by changes in hepatic insulin extraction.
Insulin is secreted in a pulsatile manner resulting in detection of high-frequency insulin concentration oscillations in the peripheral circulation (1), together with ultradian oscillations (2,3). These high-frequency oscillations are caused by interislet coordinated insulin secretory bursts, at a frequency of 515 min per pulse (1,4,5). The contribution of these insulin secretory bursts to overall insulin secretion has been quantified in a canine model by direct sampling across the pancreas (5) and in a human model employing high-frequency sampling, a highly specific insulin assay, and validated deconvolution analysis (6). In both species, the contribution of pulsatile insulin secretion is at least 7075%, and changes in overall insulin secretion after stimulation (7) and inhibition (8) are primarily through modulations in the pulsatile component of insulin secretion via changes in the amount of insulin released and/or the frequency of insulin secretory bursts. Increased actions of insulin on muscle (9), adipose (10), and liver (11) tissues have been reported when the hormone is delivered in a pulsatile versus a constant manner, indicating a possible role of the insulin release pattern in the modulation of insulin action at circumstances with special needs in terms of glucose homeostasis. At long-term fasting, the glucose concentration needs to be within a normal range in order to ensure normal glucose delivery to the brain and other (mainly) glucose-dependent tissues, but glucose-sparing metabolism is needed in other tissues. Therefore, by using a validated deconvolution analysis, we sought to examine the mechanisms by which the physiologically pulsatile insulin release is modulated to meet the special needs for the insulinization of insulin-sensitive tissues when glucose metabolism is brought to a minimum.
Subjects and design The protocol was approved by the Ethical Committee of Aarhus County and was performed in accordance with the Helsinki Declaration. A total of seven healthy volunteers (mean age 24 ± 2 years, two women, five men, mean BMI 23 ± 2 kg/m2) were studied. They had no family history of diabetes and were not on any medication. The volunteers were on a weight-maintaining diet for at least 3 days before the beginning of each study day. The volunteers were not allowed to perform exercise during same time period. In a randomly assigned order and with at least 4 weeks of washout, they were studied after either an overnight fast (10 h), designated as control, or a long-term fast (58 h), referred to as fasting. After the fasting period (10 vs. 58 h) they were brought to the Research Unit, Institute of Experimental Clinical Research, Aarhus University Hospital, placed in bed, and a 14-gauge catheter was placed in each antecubital vein for infusion and sampling purposes. After catheter placement, we started blood sampling from a peripheral vein every minute for 75 min. At 75 min, glucose (2.5 mg · kg-1 · min-1) was commenced and samples were collected every minute from time 115190 min. Sampling procedures have been validated (6).
Assays
Insulin.
Data analysis
Statistics
Concentrations Data on the concentration of glucose, C-peptide, insulin, glucagon, and growth hormone are given in Table 1. As expected, glucose concentrations were lower at fasting, resulting in lower insulin secretion reflected in lower C-peptide concentrations. Despite this, insulin concentrations were similar, C-peptide concentrations were lower, and, as a result, insulin/C-peptide ratios were significantly higher at fasting, even during hyperglycemia, possibly reflecting the fact that hepatic insulin extraction is reduced at fasting. The possible impact of differences in glycemia was abolished by glucose infusion resulting in very similar glucose concentrations, allowing the study of the impact of higher counterregulatory hormones and preceding long-term fasting. The insulin concentration time series showed dynamic high frequency changes before glucose infusion at both fasting and control study, and these oscillations were retained or increased by the constant glucose infusion. At long-term fasting, the concentration of free fatty acids increased tremendously from 485 to 2,110 nmol/l (P < 0.01), indicating a physiological state of hyperlipidemia during fasting.
Secretion Data from deconvolution on overall, basal, and pulsatile insulin secretion are given in Table 2. The insulin secretion was assessed by deconvolution of serial serum insulin concentration measurements and revealed the presence of discrete punctual insulin secretory bursts that were superimposed on a basal insulin secretion in all studies. The overall insulin secretion was reduced by 50% before glucose infusion in the fasting versus the control study, due to decreased basal and pulsatile secretion. Glucose infusion resulted in very similar insulin secretion patterns on the two study days. It is of interest that the frequency on both occasions increased with glucose infusion, indicating a glucose-sensitive pacemaker that triggers the pulsatile insulin release. It is also important to notice that the pulsatile pattern was altered via marked attenuation of the pulse mass and amplitude, which will be relevant to the understanding of the hepatic insulin exposure.
In the present study, the insulin release process was assessed in seven healthy humans at basal and fasting conditions using previously validated methods (6). The insulin concentration time series were analyzed using of deconvolution in order to assess the changes in the insulin-release process after long-term fasting. In addition, the impact of acute modest hyperglycemia was tested at each of the above conditions. The deconvoluted insulin secretory patterns show that the release of insulin at fasting is adapted to needs by reduction in the amplitude and frequency of the secretory burst mass. The preserved release pattern as dominant common secretory bursts, rather than time-invariant basal secretion, indicate that the controlling mechanisms for coordinated (physiological) release are intact, even at this state of low glucose and high free fatty acid concentrations, as well as (physiological) insulin resistance. Free fatty acids are known to stimulate the release of insulin, but the release pattern was still pulsatile in accordance with in vitro data suggesting cyclic glycolysis driving the oscillatory insulin release pattern (14). Also, this may indicate that short-term (approximate 48 h) exposure to high concentrations of free fatty acids does not perturb the ß-cell oscillatory release process, suggesting that hyperlipidemia is not causing impaired pulsatile insulin secretion, as observed in type 2 diabetes. The pulsatile release of insulin from the ß-cell population likely reflects the result of simultaneous metabolic processes in the ß-cell population. These metabolic processes are known to (at least) involve cyclic glycolysis, with subsequent changes in intracellular ATP concentrations, causing closure of ATP-dependent potassium channels, depolarization of the ß-cell membrane, a rise in intracellular calcium (through one or more mechanisms), and exocytosis of insulin-containing granules. Because in vivo pulsatile insulin release frequency is influenced by plasma glucose concentrations, as observed here and reported previously (7), glucose concentration changes may affect the metabolic processes in vivo, either directly or through nerves and/or other metabolites and hormones. The change in insulin-C/peptide ratio reported herein may reflect that attenuated insulin secretory burst mass is accompanied by reduced hepatic insulin extraction, as has previously been reported for somatostatin-induced inhibition of insulin pulse amplitude (8). The reduced glucose concentration could be expected to influence the insulin glucose feedback system (15,16), but, in this case, pulsatile insulin secretion was still preserved. We conclude that at long-term fasting, insulin secretion is adjusted by a reduction in pulse mass and amplitude, accompanied by increased insulin-C/peptide ratio. The pulsatile release is preserved despite very high concentrations of free fatty acids, glucagon, and growth hormone, despite insulin resistance.
Address correspondence and reprint requests to porksen{at}dadlnet.dk. Accepted for publication 5 June 2001. ELISA, enzyme-linked immunosorbent assay. The symposium and the publication of this article have been made possible by an unrestricted educational grant from Servier, Paris.
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||